Systematic reviews and meta‐analyses indicate that PD‐1 inhibitors significantly increase the risk of hypothyroidism, pneumonitis, colitis, and hypophysitis, though severe organ‐specific irAEs remain uncommon overall [228]. This evidence concerns the gene PDCD1 and colitis.